Why is the Avita Medical share price rocketing 24% today?

This healthcare share is ending the week on a very positive note. But why?

| More on:
Vanadium Resources share price person riding rocket indicating share price increase

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Avita Medical Inc (ASX: AVH) share price is catching the eye on Friday.

In morning trade, the regenerative medicine company's shares are up 24% to $3.96.

Why is the Avita Medical share price rocketing?

Investors have been picking up Avita Medical's shares this morning after it released its third quarter update and revealed strong top line growth.

Here's a summary of how it performed for the three months ended 30 September:

  • Commercial revenue up 51% to US$13.5 million
  • Gross margin of 84.5% for the quarter
  • Operating expenses up 48% to US$21 million
  • Net loss widened 55% to US$8.7 million
  • Cash on hand of US$60.1 million

Despite its sizeable loss, management believes the regenerative medicine company is well-positioned and has sufficient cash to meet its profitability goals. This could explain the strong rise in the Avita Medical share price today.

This should be supported by the Recell Go product, which management appears confident will be granted US FDA approval next year.

The company's chief executive officer, Jim Corbett, commented:

We continue to execute our growth strategy, paving the way to profitability. We are diligently working through supplemental in-house testing to support the FDA's review of our PMA supplement for RECELL GO. Once complete, we expect to submit a response to the FDA's open questions on February 28, 2024. Under the Breakthrough Device program, we anticipate FDA approval on May 30, 2024, which positions us for a launch the following day.

This sentiment was echoed by its chief financial officer, David O'Toole, he adds:

We have achieved significant commercial revenue growth rates for the last three quarters of 40%, 42% and 51%, respectively, over the same periods in the previous year. Further, we remain confident that our cash reserves position us to achieve our goals and reach profitability in 2025.

Looking ahead, the company expects its strong top-line growth to continue. It is guiding to fourth-quarter commercial revenue growth of 64% to 73% over the prior corresponding period.

Following today's gain, the Avita Medical share price is now up 100% in 2023.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical. The Motley Fool Australia has recommended Avita Medical. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

ASX 200 healthcare stock surges amid new takeover rumours

Takeover rumours are circling again for this company.

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

'Next decade is likely to be a golden era' for ASX shares in this sector

This stock is expected to deliver healthy returns according to a fund manager.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Guess which ASX biotech stock is surging 11% on big FDA news

Paradigm made a big step towards treating knee osteoarthritis.

Read more »

healthcare worker overseeing group of aged care residents at table
Share Gainers

This ASX All Ords share has sneakily climbed 128% over the past year

Investors have sent this under-the-radar ASX All Ords stock flying higher. But why.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

UBS says buy CSL shares for a double-digit return in 2025

This ASX giant could create healthy returns, according to a leading broker.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

1 big factor to keep in mind before buying Pro Medicus shares

Investors would be wise to consider this metric.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

ASX All Ords share higher despite major shareholder cashing out 30% stake

Investors in this ASX All Ords healthcare share appear unperturbed by news of a major sell-down.

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development
Healthcare Shares

Up 24% in a month! This ASX biotech share is hitting a record high on trial update

The SECuRE trial is getting investors excited. Here's the latest.

Read more »